Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

We've identified the following companies as similar to Novo Nordisk A/S because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to ...

Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...